These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 30936102)

  • 21. Polymyxin: Alternative Mechanisms of Action and Resistance.
    Trimble MJ; Mlynárčik P; Kolář M; Hancock RE
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27503996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
    Galea CA; Han M; Zhu Y; Roberts K; Wang J; Thompson PE; L J; Velkov T
    J Nat Prod; 2017 May; 80(5):1264-1274. PubMed ID: 28463513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes.
    Velkov T; Yun B; Schneider EK; Azad MA; Dolezal O; Morris FC; Nation RL; Wang J; Chen K; Yu HH; Wang L; Thompson PE; Roberts KD; Li J
    ACS Infect Dis; 2016 May; 2(5):341-51. PubMed ID: 27627202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymyxin antibiotics for gram-negative infections.
    Arnold TM; Forrest GN; Messmer KJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of polymyxin resistance through the food chain, the global crisis.
    Ray M; Manjunath A; Halami PM
    J Antibiot (Tokyo); 2022 Apr; 75(4):185-198. PubMed ID: 35079146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymyxin susceptibility testing, interpretative breakpoints and resistance mechanisms: An update.
    Bakthavatchalam YD; Pragasam AK; Biswas I; Veeraraghavan B
    J Glob Antimicrob Resist; 2018 Mar; 12():124-136. PubMed ID: 28962863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
    Doymaz MZ; Karaaslan E
    Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
    [No Abstract]   [Full Text] [Related]  

  • 30. Drown Them in Their Own Garbage: a New Strategy To Reverse Polymyxin Resistance?
    May KL
    J Bacteriol; 2022 Feb; 204(2):e0057421. PubMed ID: 34843378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
    Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
    Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Advances in the Development of Polymyxin Antibiotics: 2010-2023.
    Slingerland CJ; Martin NI
    ACS Infect Dis; 2024 Apr; 10(4):1056-1079. PubMed ID: 38470446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD; Suresh K
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria.
    Tsubery H; Yaakov H; Cohen S; Giterman T; Matityahou A; Fridkin M; Ofek I
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3122-8. PubMed ID: 16048913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
    Evans ME; Feola DJ; Rapp RP
    Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
    Zavascki AP
    Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The action of combinations of the nonapeptide polymyxin B with antibiotics on gram-negative bacteria].
    Bairamashvili DI; Zinchenko AA; Maslin DN; Trakhanova MN; Miroshnikov AI
    Antibiot Khimioter; 1988 Aug; 33(8):591-4. PubMed ID: 2848467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.